ALX Oncology Holdings Inc
ALXO
查看详细走势图
1.450USD
+0.040+2.84%
收盘 12/19, 16:00（美东）报价延迟15分钟
77.69M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.84%
5天
-1.36%
1月
+1.40%
6月
+199.59%
今年开始到现在
-13.17%
1年
-10.49%
查看详细走势图
TradingKey ALX Oncology Holdings Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
ALX Oncology Holdings Inc当前公司基本面数据相对谨慎，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名112/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价3.00。中期看，股价处于下降通道。近一个月，市场表现一般，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
ALX Oncology Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
5
位分析师
买入
评级
3.000
目标均价
+108.33%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
ALX Oncology Holdings Inc亮点
亮点风险
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
估值合理
公司最新PE估值-0.72，处于3年历史合理位
机构加仓
最新机构持股35.78M股，环比增加1.57%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值164.50K
活跃度增加
近期活跃度增加，过去20天平均换手率0.59
ALX Oncology Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
ALX Oncology Holdings Inc简介
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
公司代码ALXO
公司ALX Oncology Holdings Inc
CEOLettmann (Jason)
网址https://alxoncology.com/
常见问题
ALX Oncology Holdings Inc(ALXO)的当前股价是多少？
ALX Oncology Holdings Inc(ALXO)的当前股价是 1.450。
ALX Oncology Holdings Inc的股票代码是什么？
ALX Oncology Holdings Inc的股票代码是ALXO。
ALX Oncology Holdings Inc股票的52周最高点是多少？
ALX Oncology Holdings Inc股票的52周最高点是2.270。
ALX Oncology Holdings Inc股票的52周最低点是多少？
ALX Oncology Holdings Inc股票的52周最低点是0.404。
ALX Oncology Holdings Inc的市值是多少？
ALX Oncology Holdings Inc的市值是77.69M。
ALX Oncology Holdings Inc的净利润是多少？
ALX Oncology Holdings Inc的净利润为-134.85M。
现在ALX Oncology Holdings Inc(ALXO)的股票是买入、持有还是卖出？
根据分析师评级，ALX Oncology Holdings Inc(ALXO)的总体评级为买入，目标价格为3.000。
ALX Oncology Holdings Inc(ALXO)股票的每股收益（EPS TTM）是多少
ALX Oncology Holdings Inc(ALXO)股票的每股收益（EPS TTM）是-2.009。
相关品种
